| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0251 | BX647187 | prostate cancer | qPCR, Western bolt, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, PC3, Du145) | differential expression | interaction | Our results showed that Hec1 mRNA and protein were significantly overexpressed in Human PCa tissues and several PCa cell lines. Silencing Hec1 markedly suppressed proliferation, promoted apoptosis and induced cell-cycle arrest in G2/M-phase in PCa cells. Through bioinformatics analysis and knockdown Hec1 in PCa cells, we found LncRNA BX647187 was positively regulated by Hec1. We further demonstrated that suppression of BX647187 in PCa cells significantly reduced cell proliferation and promoted apoptosis. | 26612002 | Lnc2Cancer |
| EL0257 | PCOTH | prostate cancer | qPCR, Northern blot etc. | prostate cancer tissue, cell lines (LNCaP, DU145, PC-3CaP etc.) | up-regulated | expression | PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. | 15930275 | LncRNADisease Lnc2Cancer |
| EL0274 | CBR3-AS1 | prostate cancer | N/A | N/A | N/A | regulation | Oncogene; putative therapeutic target | 24373479 | LncRNADisease |
| EL0274 | CBR3-AS1 | prostate cancer | qPCR, Western blot etc. | cell line (LNCaP, PC-3, C4-2 etc.) | up-regulated | Interaction | The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 (CBR3-AS1) modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. | 22264502 | LncRNADisease Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate | 22817756 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | regulation | Gene silencing of INK4b-ARF-INK4a and p15/CDKN2B by recruitment of PRC1 and PRC2. | 22996375 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | ANRIL, also upregulated in prostate cancer, is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15. | 23463798 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT1: colorectal cancer). | 23660942 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | regulation | ANRIL is an antisense lncRNA elevated in PCa that overlaps this locus, interacting directly with polycomb repressive complex 1 and histone H3K27 methylation to repress CDKN2A-CDKN2B expression | 24146262 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | N/A | Long ncRNA antisense non-coding RNA in the INK4 locus (ANRIL) has been associated to hereditary cutaneous malignant melanoma, prostate cancer and tumors of the neural system (Pasmant et al., 2011). | 24624135 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | prostate cancer | N/A | N/A | N/A | expression | ANRIL is upregulated in prostate cancer and is required for the repression of the tumor suppressors INK4a/p16 and INK4b/p15 (Yap et al., 2010; Kotake et al., 2011). | 24721780 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | prostate cancer | qPCR etc. | cell lines (PC3, MEFs, IMR90 etc.) | up-regulated | Interaction | Here we report that chromobox 7 (CBX7) within the polycomb repressive complex 1 binds to ANRIL, and both CBX7 and ANRIL are found at elevated levels in prostate cancer tissues. | 20541999 | LncRNADisease Lnc2Cancer |
| EL0309 | AC021078.1 | prostate cancer | integrating analysis of sequence features and gene expression profiles | prostate cancer | N/A | N/A | The tumour-suppressive function of two lncRNAs (TUG1 and CTB-89H12.4) and their regulation of PTEN expression in prostate cancer. | 26975529 | |
| EL0310 | CTBP1-AS | prostate cancer | N/A | N/A | N/A | regulation | Oncogene | 24373479 | LncRNADisease |
| EL0310 | CTBP1-AS | prostate cancer | N/A | N/A | N/A | regulation | The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. | 24531795 | LncRNADisease |
| EL0310 | CTBP1-AS | prostate cancer | qPCR, Western bolt, Northern bolt, RIP etc. | prostate cancer tissue, cell lines (VCaP, LNCaP, DU145, RWPE etc.) | up-regulated | N/A | CTBP1-AS is predominantly localized in the nucleus and its expression is generally upregulated in prostate cancer. CTBP1-AS promotes both hormone-dependent and castration-resistant tumour growth. Mechanistically, CTBP1-AS directly represses CTBP1 expression by recruiting the RNA-binding transcriptional repressor PSF together with histone deacetylases. CTBP1-AS also exhibits global androgen-dependent functions by inhibiting tumour-suppressor genes via the PSF-dependent mechanism thus promoting cell cycle progression. | 23644382 | Lnc2Cancer |
| EL0329 | DANCR | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0356 | DRAIC | prostate cancer | qPCR, Western blot etc. | cell lines (VCap, PC3M-luc, LNCaP etc.) | down-regulated | N/A | The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus. Prostate cancers persisting in patients after androgen deprivation therapy (ADT) select for decreased DRAIC expression, and higher levels of DRAIC in prostate cancer are associated with longer disease-free survival (DFS). DRAIC expression predicts good prognosis in a wide range of malignancies, including bladder cancer, low-grade gliomas, lung adenocarcinoma, stomach adenocarcinoma, renal clear cell carcinoma, hepatocellular carcinoma, skin melanoma, and stomach adenocarcinoma. | 25700553 | LncRNADisease Lnc2Cancer |
| EL0366 | EGOT | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0510 | FR0257520 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | down-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
| EL0511 | FR0348383 | prostate cancer | qRT-PCR | Post-digital rectal examination (DRE) first-catch urine specimens prior to prostate biopsies | up-regulated | expression | FR0348383 transcript in post-DRE urine may be a novel biomarker for detection of PCa with great diagnostic value, especially in the grey zone cohort. | 25597901 | |
| EL0511 | FR0348383 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | up-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
| EL0526 | GAS5 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0526 | GAS5 | prostate cancer | N/A | N/A | N/A | expression | Tumour suppressor; putative oncogene host | 24373479 | LncRNADisease |
| EL0526 | GAS5 | prostate cancer | qPCR etc. | cell lines (HEK 293T, LNCaP, W7.2c etc.) | down-regulated | mutation | Chromosomal translocations affecting the 1q25 locus containing the Gas5 gene have been detected in melanoma, B-cell lymphoma, and prostate and breast cancer. | 18836484 | LncRNADisease Lnc2Cancer |
| EL0526 | GAS5 | prostate cancer | qPCR, knockdown etc. | cell lines (22Rv1, PC-3 etc.) | up-regulated | N/A | GAS5 promotes the apoptosis of prostate 34 cells, and exonic sequence, i.e. GAS5 lncRNA, is sufficient to mediate this activity. Abnormally low levels of 35 GAS5 expressionmay therefore reduce the effectiveness of chemotherapeutic agents. | 23676682 | Lnc2Cancer |
| EL0526 | GAS5 | prostate cancer | siRNA | prostate cancer cells | up-regulated | expression | mTOR inhibition enhances GAS5 transcript levels in certain prostate cancer cell lines. This selectivity is likely to be related to endogenous GAS5 expression levels. | 25650269 | |
| EL0556 | H19 | prostate cancer | N/A | N/A | N/A | expression | Putative susceptibility and diagnostic marker | 24373479 | LncRNADisease |
| EL0556 | H19 | prostate cancer | qPCR etc. | cell lines ((Du-145, PC-3) | down-regulated | N/A | Comparing with respective normal cell line, H19 was found highly expressed in stomach cancer cell lines (AGS, MGC-803 and SGC-7901) and hepatocellular carcinoma cell lines (SMMC-7721 and HepG2), while lowly expressed in lung cancer cell line (A549) and prostate cancer cell lines (Du-145 and PC-3). | 24063685 | Lnc2Cancer |
| EL0556 | H19 | prostate cancer | qPCR, Western blot etc. | cell lines (P69, M12) | down-regulated | N/A | In this study, we found that long non-coding RNA H19 (H19) and H19-derived microRNA-675 (miR-675) were significantly downregulated in the metastatic prostate cancer cell line M12 compared with the non-metastatic prostate epithelial cell line P69. Upregulation of H19 in P69 and PC3 cells significantly increased the level of miR-675 and repressed cell migration; however, ectopic expression of H19 in M12 cells could not increase the level of miR-675 and therefore had no effect on cell migration. | 24988946 | Lnc2Cancer |
| EL0578 | HOTAIR | prostate cancer | microarray, qPCR etc. | prostate cancer tissue, cell lines (LNCaP, PC3, DU145, RWPE-1 etc.) | up-regulated | N/A | LncRNA profiling showed that HOTAIR was highly regulated by genistein and its expression was higher in castration-resistant PCa cell lines than in normal prostate cells. Knockdown (siRNA) of HOTAIR decreased PCa cell proliferation, migration and invasion and induced apoptosis and cell cycle arrest. miR-34a was also up-regulated by genistein and may directly target HOTAIR in both PC3 and DU145 PCa cells. Our results indicated that genistein inhibited PCa cell growth through down-regulation of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a. These findings enhance understanding of how genistein regulates lncRNA HOTAIR and miR-34a in PCa. | 23936419 | Lnc2Cancer |
| EL0578 | HOTAIR | prostate cancer | qPCR, RNA Pull-Down Assay, RIP, ChIP etc. | prostate cancer tissue | up-regulated | interaction | Here, we report HOTAIR as an androgen-repressed lncRNA, and, as such, it is markedly upregulated following androgen deprivation therapies and in CRPC. Functionally, HOTAIR overexpression increases, whereas HOTAIR knockdown decreases, prostate cancer cell growth and invasion. Taken together, our results provide compelling evidence of lncRNAs as drivers of androgen-independent AR activity and CRPC progression, and they support the potential of lncRNAs as therapeutic targets. | 26411689 | Lnc2Cancer |
| EL0582 | HOTTIP | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0582 | HOTTIP | prostate cancer | sciliencing or knockdown of HOTTIP | prostate cancer tumorigenesis | down-regulated | N/A | down-regulation of HOTTIP and HOXA13 was associated with cell growth and cell cycle. | 27064878 | |
| EL0600 | HULC | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0608 | IGF2-AS | prostate cancer | N/A | N/A | N/A | mutation | Association identified by GWAS. | 19767753 | LncRNADisease |
| EL0628 | KCNQ1OT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0673 | LINC00963 | prostate cancer | microarray, qPCR, knockdown, Western blot etc. | cell lines (LNCaP ,C4-3) | up-regulated | regulation | Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. | 24691949 | LncRNADisease Lnc2Cancer |
| EL0704 | LINC01564 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
| EL0777 | lnc-MX1-1 | prostate cancer | real-time quantitative PCR, knockdown | prostate cancer cells | up-regulated | expression | There was a significant association between over-expression of lnc-MX1-1 and patients' clinical features such as PSA, Gleason score, metastasis, and recurrence free survival. knockdown of lnc-MX1-1 reduced both proliferation and invasiveness of LNCaP and 22Rv1 cells. | 26797523 | |
| EL0814 | LOC100287482 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
| EL0830 | LOC400891 | prostate cancer | lncRNAs expression chips screening, quantitative real-time PCR (qRT-PCR) | prostate cancer (Pca) tissues and cell lines | up-regulated | expression | Knockdown of LOC400891 could inhibit cell proliferation, migration, and invasion in vitro study. | 26797783 | |
| EL0853 | MALAT1 | prostate cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
| EL0853 | MALAT1 | prostate cancer | N/A | N/A | N/A | regulation | Putative marker | 24373479 | LncRNADisease |
| EL0853 | MALAT1 | prostate cancer | qPCR etc. | prostate cancer tissue, cell lines (22RV1, LNCAP-AI etc.) | up-regulated | N/A | MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. | 23845456 | Lnc2Cancer |
| EL0853 | MALAT1 | prostate cancer | qPCR, Northern bolt etc. | prostate cancer tissue, cell lines (LNCap-AD, 22Rv1, PC-3, DU145, C4-2 etc.) | up-regulated | N/A | qPCR was used to assess the PCA3 and MALAT-1 expression levels in an additional set of 10 pairs of PCa and adjacent normal tissues. Comparing the PCA3 and MALAT-1 expression levels in the 10 paired tissue samples revealed that PCA3 and MALAT-1 were highly expressed in most of the PCa tissues. Plasma lncRNAs probably exist in the form of fragments in a stable form. MD-miniRNA enters cell culture medium at measurable levels, and MD-miniRNA derived from human PCa xenografts actually enters the circulation in vivo and can be measured to distinguish xenografted mice from controls. | 23726266 | Lnc2Cancer |
| EL0853 | MALAT1 | prostate cancer | qPCR, RIP-Seq, knockdown, ChIP etc. | cell lines (C4-2, PC-3, LNCaP) | up-regulated | interaction | We showed that MALAT1 enhances expression of PRC2-independent target genes of EZH2 in CRPC cells in culture and patient-derived xenografts. Together, these data indicate that MALAT1 may be a crucial RNA cofactor of EZH2 and that the EZH2-MALAT1 association may provide a new avenue for development new strategies for treatment of CRPC. | 26516927 | Lnc2Cancer |
| EL0853 | MALAT1 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | up-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
| EL0861 | MEG3 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0861 | MEG3 | prostate cancer | qPCR, ISH etc. | prostate cancer tissue | down-regulated | N/A | MEG3 mRNA is expressed in the normal human fibroblast cells but is undetectable in human cancer cell lines by Northern blot. Lanes 110, Human carcinoma cells HeLa, MCF-7, T47-D, T24, 5637, Du145, K562, HT29, H1299, H4; lanes 11 and 12, human normal fibroblasts HS-27 and WI38. | 14602737 | LncRNADisease Lnc2Cancer |
| EL0861 | MEG3 | prostate cancer | qPCR, Western blot, knockdown, Flow cytometry assay etc. | prostate cancer tissue, cell lines (PC3, Du145) | down-regulated | interaction | MEG3 decreased significantly in prostate cancer tissues relative to adjacent normal tissues. MEG3 inhibited intrinsic cell survival pathway in vitro and in vivo by reducing the protein expression of Bcl-2, enhancing Bax and activating caspase 3. We further demonstrated that MEG3 inhibited the expression of cell cycle regulatory protein Cyclin D1 and induced cell cycle arrest in G0/G1 phase. | 26610246 | Lnc2Cancer |
| EL0973 | NEAT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL0973 | NEAT1 | prostate cancer | RNA-seq, qPCR, ChIP etc. | prostate cancer tissue, cell lines (LnCaP, PC3) | up-regulated | expression | Among putatively ERa-regulated intergenic long non-coding RNAs (lncRNAs), we identified nuclear enriched abundant transcript 1 (NEAT1) as the most significantly overexpressed lncRNA in prostate cancer. Prostate cancer cells expressing high levels of NEAT1 were recalcitrant to androgen or AR antagonists. NEAT1 drives oncogenic growth by altering the epigenetic landscape of target gene promoters to favour transcription. | 25415230 | Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | Measurement of lncRNA PCA3 in patient urine samples has been shown to allow more sensitive and specific diagnosis of prostate cancer than the widely used marker prostate-specific antigen (PSA). | 15245811 | LncRNADisease |
| EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | The PCA3 assay is insensitive to pre-analytical factors, performs well analytically and correctly classifies a high percent of subjects with known prostate cancer status across research sites. | 18054202 | LncRNADisease |
| EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa. | 18602209 | LncRNADisease |
| EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | Patients with a positive biopsy showed significantly higher PCA3 values. | 20424427 | LncRNADisease |
| EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | PCA3 scores were significantly lower in low-volume disease and insignificant PCa. Higher PCA3 scores were associated with aggressive disease. | 20980098 | LncRNADisease |
| EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | expression | Diagnostic marker | 24373479 | LncRNADisease |
| EL1051 | PCA3 | prostate cancer | N/A | N/A | N/A | N/A | PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 2) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. | 24667321 | LncRNADisease |
| EL1051 | PCA3 | prostate cancer | Northern blot etc. | prostate cancer tissue | up-regulated | expression | PCA3 is a highly prostate cancer-specific gene. | 14607216 | LncRNADisease Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | PROGENSA PCA3 assay etc. | blood, urine | up-regulated | expression | A PCA3 score threshold of 20 may have the highest utility for selecting men with clinically insignificant prostate cancer in whom active surveillance may be appropriate; a PCA3 score threshold of 50 may be used to identify men at high risk of harbouring significant prostate cancer who are candidates for RP. | 21883822 | LncRNADisease Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | Upregulation of two new PCA3 isoforms in PCa tissues improves discrimination between PCa and BPH. | 19319183 | LncRNADisease Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | PCA3 mRNA is prostate cancer specific and shows increased expression in prostate cancer. | 20114043 | LncRNADisease Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | It was found that the levels of the mRNA expression of DD3(PCA3) were significantly higher (p<0.045) in patients with PCa than in patients with benign prostatic hyperplasia. | 20332487 | LncRNADisease Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | qPCR etc. | blood | differential expression | mutation | The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region may be a risk factor for prostate cancer in the Chinese population. | 21655300 | LncRNADisease Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | qPCR, in vitro knockdown etc. | cell lines (LNCaP, PC3, RWPE-1, PrEC etc.) | up-regulated | N/A | PCA3 is a non-coding RNA (ncRNA) that is highly expressed in prostate cancer (PCa) cells, LNCaP siPCA3-transfected cells significantly inhibited cell growth and viability, and increased the proportion of cells in the sub G0/G1 phase of the cell cycle and the percentage of pyknotic nuclei, compared to those transfected with scramble siRNA (siSCr)-transfected cells. Our findings suggest that the ncRNA PCA3 is involved in the control of PCa cell survival, in part through modulating AR signaling, which may raise new possibilities of using PCA3 knockdown as an additional therapeutic strategy for PCa control. | 23130941 | Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | qPCR, Northern blot etc. | BPH, prostatic tumor tissue | up-regulated | expression | PCA3 is one of the most prostate cancer-specific genes yet described, and this makes DD3 a promising marker for the early diagnosis of prostate cancer and provides a powerful tool for the development of new treatment strategies for prostate cancer patients. | 10606244 | LncRNADisease Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | qPCR, Northern bolt etc. | prostate cancer tissue, cell lines (LNCap-AD, 22Rv1, PC-3, DU145, C4-2 etc.) | up-regulated | N/A | qPCR was used to assess the PCA3 and MALAT-1 expression levels in an additional set of 10 pairs of PCa and adjacent normal tissues. Comparing the PCA3 and MALAT-1 expression levels in the 10 paired tissue samples revealed that PCA3 and MALAT-1 were highly expressed in most of the PCa tissues. Plasma lncRNAs probably exist in the form of fragments in a stable form. MD-miniRNA enters cell culture medium at measurable levels, and MD-miniRNA derived from human PCa xenografts actually enters the circulation in vivo and can be measured to distinguish xenografted mice from controls. | 23726266 | Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | RNA-seq, qPCR etc. | prostate cancer tissue | up-regulated | N/A | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. | 22349460 | Lnc2Cancer |
| EL1051 | PCA3 | prostate cancer | Sequencing etc. | prostate cancer tissue, blood(leukocytes) | up-regulated | N/A | By PCR-based cloning and sequencing in paired peripheral blood leukocytes and prostate tissues,5 PCA3 TAAA STR polymorphisms and 8 genotypes were found in both peripheral blood leukocytes and prostate tissues, the carriers with more TAAA repeats were associated with increased risk for PCa than individuals having less TAAA repeats | 25445501 | LncRNADisease Lnc2Cancer |
| EL1052 | PCAT1 | prostate cancer | microarray, qPCR, Western blot, knockdown, Luciferase reporter assay etc. | prostate tissue, cell lines (Du145-derived, RWPE-derived, LNCAP-derived, PC3-derived etc.) | up-regulated | regulation | PCAT1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. | 24473064 | LncRNADisease Lnc2Cancer |
| EL1052 | PCAT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL1052 | PCAT1 | prostate cancer | N/A | N/A | N/A | regulation | They described PCAT1,a novel PCa lincRNA on 8q24, in the locality of well-characterized PCa risk-related SNPs and the c-MYC oncogene. | 24146262 | LncRNADisease |
| EL1052 | PCAT1 | prostate cancer | N/A | N/A | N/A | expression | Putative marker and oncogene | 24373479 | LncRNADisease |
| EL1052 | PCAT1 | prostate cancer | N/A | N/A | N/A | regulation | The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. | 24531795 | LncRNADisease |
| EL1052 | PCAT1 | prostate cancer | qPCR, Luciferase reporter assay, knockdown etc. | cell lines (LNCaP) | up-regulated | regulation | We show that PCAT-1 promotes prostate cell proliferation and that this phenotype is mediated through up-regulation of the cMyc protein (encoded by the MYC gene). Antagonism of cMyc is able to reverse PCAT-1mediated cell proliferation. We show that PCAT-1 regulates cMyc post-transcriptionally through the MYC 3' untranslated region (UTR). Further, we find a protetcive effetc of PCAT-1 on cMyc by interfering with the regulation of MYC by miR-34a. | 25425964 | Lnc2Cancer |
| EL1052 | PCAT1 | prostate cancer | RNA-seq, qPCR, Western blot etc. | prostate cancer tissue, cell lines (VCaP, LNCaP) | up-regulated | expression | PCAT1 is markedly overexpressed in a subset of prostate cancers, particularly metastases, and may contribute to cell proliferation in these tumors. | 21804560 | LncRNADisease Lnc2Cancer |
| EL1053 | PCAT18 | prostate cancer | microarray, qPCR, knockdown etc. | cell lines (LTL313B, LTL313H etc.) | up-regulated | expression | The most highly up-regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues (p<0.05) and up-regulated in PCa compared to 15 other neoplasms (p<0.001). | 24519926 | LncRNADisease Lnc2Cancer |
| EL1054 | PCAT29 | prostate cancer | microarray, qPCR etc. | cell lines (Glutamax(Invitrogen), LNCaP, DU145 etc.) | down-regulated | N/A | PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. PCAT29 as an androgen-regulated tumor suppressor in prostate cancer. | 25030374 | Lnc2Cancer |
| EL1054 | PCAT29 | prostate cancer | qPCR, Western blot etc. | cell lines (VCap, PC3M-luc, LNCaP etc.) | down-regulated | N/A | This study reveals a novel tumor suppressive locus encoding two hormone-regulated lncRNAs, DRAIC and PCAT30, that are prognostic for a wide variety of cancer types.This study reveals a novel tumor suppressive locus encoding two hormone-regulated lncRNAs, DRAICand PCAT29, that are prognostic for a wide variety of cancer types. | 25700553 | LncRNADisease Lnc2Cancer |
| EL1055 | PCAT5 | prostate cancer | RNA-seq, qPCR, knockdown etc. | cell lines (PC-3, 22Rv1) | up-regulated | interaction | In vitro validation of these alterations revealed a complex integrated phenotype affecting cell growth, migration, invasion, colony-forming potential and apoptosis. Our findings reveal a key molecular determinant of differences between PC and CRPC at the level of the transcriptome. Further, they establish PCAT5 as a novel oncogenic lncRNA in ERG-positive prostate cancers, with implications for defining CRPC biomarkers and new therapeutic interventions. | 26282172 | Lnc2Cancer |
| EL1056 | PCAT6 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Both lncRNA showed positive correlation between gene expression and SCNA. The criteria of increasing expression from normal to primary to metastatic prostate cancer aimed to uncover lncRNA that may be important therapeutic targets for both primary and metastatic cancers. | 23728290 | Lnc2Cancer |
| EL1057 | PCAT7 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Both lncRNA showed positive correlation between gene expression and SCNA. The criteria of increasing expression from normal to primary to metastatic prostate cancer aimed to uncover lncRNA that may be important therapeutic targets for both primary and metastatic cancers. | 23728290 | Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | expression | PCGEM1 was originally discovered in a genome-wide gene expression screen as a cDNA sequence with prostate cancer overexpression and highly specific localization to glandular epithelial cells. | 20951849 | LncRNADisease |
| EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | regulation | One of the earliest lncRNAs described in PCa, was PCGEM1(prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). One of the earliest lncRNAs described in PCa, was PCGEM1 (prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). | 24146262 | LncRNADisease |
| EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | regulation | High-risk and predictive marker Oncogene | 24373479 | LncRNADisease |
| EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | N/A | PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 1) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. | 24667321 | LncRNADisease |
| EL1058 | PCGEM1 | prostate cancer | N/A | N/A | N/A | regulation | The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). | 24713835 | LncRNADisease |
| EL1058 | PCGEM1 | prostate cancer | Northern blot etc. | cell line (LNCaP) | up-regulated | N/A | A prostate-specific and prostate cancer-associated noncoding gene, PCGEM1 regulates apoptosis. | 16569192 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. | 14724589 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | The biomarkers had sensitivities ranging from 91% to 100%. Clinical specificities evaluated with the BPH tissue were the following: hTERT mRNA (93%), DD3 mRNA (57%), Survivin (29%) and PCGEM1 (14%). | 16515751 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR etc. | cell lines (PC-3, DU145 etc.) | up-regulated | Interaction | Phytosterol inhibition of PCGEM1 and cell growth and the overexpression of caveolin-1, suggests that poor disease prognosis anchors on the ability of caveolin-1 to regulate downstream oncogene(s) and apoptosis genes. | 19186008 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | Expression profiles of genes in CRPC support a role for the transcriptional activity of the PCGEM1. | 20868494 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR etc. | prostate cancer tissue | differential expression | mutation | We found a significantly decreased risk of PCa for rs6434568 AC and AC/AA genotype, as well as rs16834898 AC and AC/CC genotype, compared with the CC and AA genotypes, respectively. | 23459097 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR etc. | cell lines (LNCaP) | up-regulated | N/A | PCGEM1 overexpression is highly associated with prostate tumors. CGEM1 tumorigenic potential has been recently shown to be in part due to its ability to activate androgen receptor (AR). Here, we report a novel function of PCGEM1 that provides growth advantages for cancer cells by regulating tumor metabolism via c-Myc activation. PCGEM1 promotes glucose uptake for aerobic glycolysis, coupling with the pentose phosphate shunt to facilitate biosynthesis of nucleotide and lipid, and generates NADPH for redox homeostasis. | 25512540 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR, Northern blot, FISH, ISH etc. | prostate cancer tissue, cell lines (LNCaP, DU145, PC-3CaP etc.) | up-regulated | expression | PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. | 11050243 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | qPCR, RIP etc. | prostate cancer tissue,cell lines (LNCaP, LNCaP-cds1, LNCaP-cds2, CWR22Rv1 etc.), tissues (prostate tumour tissues) | up-regulated | expression | Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. | 23945587 | LncRNADisease Lnc2Cancer |
| EL1058 | PCGEM1 | prostate cancer | RNA-seq, qRT-PCR | N/A | N/A | N/A | not implicated in castration resistant prostate cancer. | 24727738 | |
| EL1058 | PCGEM1 | prostate cancer | RT-PCR, luciferase reporter assay, MTT assay and flow cytometry, transwell assays | LNCaP cells and noncancerous RWPE-1 prostate cells, (nu/nu) mouse model | up-regulated | interaction | We demonstrate a reciprocal negative control relationship between PCGEM1 and miR-145 that regulates both LNCaP cell proliferation and nu/nu PCa tumor growth. | 25200485 | |
| EL1060 | PCNCR1 | prostate cancer | N/A | N/A | N/A | N/A | Accumulating evidence indicated that prostate cancer non-coding RNA 1 (PCNCR1) lncRNA was identified in a gene deserton chromosome 8q24.2 and is associated with susceptibility to prostate cancer | 22535282 | LncRNADisease |
| EL1060 | PCNCR1 | prostate cancer | N/A | N/A | N/A | N/A | PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 3) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. | 24667321 | LncRNADisease |
| EL1078 | POU5F1P4 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | N/A | POU5F1P1 was found to be the only member of the POU5F1 family to be expressed in prostate with over-expression in prostatic carcinoma compared to surrounding prostatic tissue probably because of an increased density of expressing cells. The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa. | 20017164 | Lnc2Cancer |
| EL1085 | PRINS | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL1088 | PRNCR1 | prostate cancer | N/A | N/A | N/A | regulation | That same year, Chung et al reported PCa susceptibility SNPs within a 13 kb intron-less lincRNA also on 8q24, which they termed PRNCR1. | 24146262 | LncRNADisease |
| EL1088 | PRNCR1 | prostate cancer | N/A | N/A | N/A | regulation | Susceptibility marker oncogene | 24373479 | LncRNADisease |
| EL1088 | PRNCR1 | prostate cancer | N/A | N/A | N/A | regulation | The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). | 24713835 | LncRNADisease |
| EL1088 | PRNCR1 | prostate cancer | qPCR, Northern blot etc. | cell lines (LNCaP, 22Rv1, PC-3 etc.) | up-regulated | N/A | PRNCR1 expression was upregulated in some of the PC cells as well as precursor lesion prostatic intraepithelial neoplasia. Knockdown of PRNCR1 by siRNA attenuated the viability of PC cells and the transactivation activity of androgen receptor, which indicates that PRNCR1 could be involved in prostate carcinogenesis possibly through androgen receptor activity. | 20874843 | Lnc2Cancer |
| EL1088 | PRNCR1 | prostate cancer | qPCR, RIP etc. | prostate cancer tissue,cell lines (LNCaP, LNCaP-cds1, LNCaP-cds2, CWR22Rv1 etc.), tissues (prostate tumour tissues) | up-regulated | expression | Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. | 23945587 | LncRNADisease Lnc2Cancer |
| EL1088 | PRNCR1 | prostate cancer | RNA-seq, qRT-PCR | N/A | N/A | N/A | not implicated in castration resistant prostate cancer. | 24727738 | |
| EL1097 | PTENP1 | prostate cancer | N/A | N/A | N/A | regulation | Oncogene; tumour suppressor | 24373479 | LncRNADisease |
| EL1102 | PVT1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | up-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL1102 | PVT1 | prostate cancer | qPCR, ChIP etc. | cell lines (PC3, 1542-CP) | differential expression | mutation | The risk allele (G) of rs378854 (A>G) reduces binding of the transcription factor YY1 in vitro. The region surrounding rs378854 interacts with the MYC and PVT1 promoters.Expression of the PVT1 oncogene in normal prostate tissue increased with the presence of the risk allele of rs378854, while expression of MYC was not affected. | 21814516 | LncRNADisease Lnc2Cancer |
| EL1180 | SCHLAP1 | prostate cancer | microarray, ISH etc. | prostate cancer tissue | up-regulated | N/A | SChLAP1 expression increases with prostate cancer progression,and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate and multivariate Cox regression analyses. | 25499224 | LncRNADisease Lnc2Cancer |
| EL1180 | SCHLAP1 | prostate cancer | microarray, qPCR etc. | prostate cancer tissue | up-regulated | N/A | The long non-coding RNA SChLAP1 was identified as the highest-ranked overexpressed gene in cancers with metastatic progression. | 25456366 | LncRNADisease Lnc2Cancer |
| EL1180 | SCHLAP1 | prostate cancer | N/A | N/A | N/A | expression | Prensner et al found that the lncRNA SChLAP1 was overexpresed in prostate tumors and where it is critical for tumor cell metastasis. | 24829860 | LncRNADisease |
| EL1180 | SCHLAP1 | prostate cancer | RNA-Seq, qPCR, in vitro knockdown etc. | prostate cancer tissue, prostate cell lines (PCAT-109, PCAT-114 etc.) | up-regulated | N/A | SChLAP1 contributes to the development of lethal cancer at least in part by antagonizing the tumor-suppressive functions of the SWI/SNF complex. | 24076601 | Lnc2Cancer |
| EL1240 | SPRY4-IT1 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
| EL1325 | TERC | prostate cancer | N/A | N/A | N/A | expression | TERC is expressed in all human tissues regardless of telomerase activity, whereas TERT is highly expressed in >90% of tumor cells | 24146262 | LncRNADisease |
| EL1349 | TP53COR1 | prostate cancer | qPCR etc. | prostate cancer tissue | up-regulated | expression | The lincRNA-p21 levels were significantly higher in PCa than in BPH. Our data suggest that the discriminative potential of exosomal lincRNA-p21 levels may help to improve the diagnostic prediction of the malignant state for patients with PCa. | 25999983 | Lnc2Cancer |
| EL1366 | TRPM2-AS | prostate cancer | microarray, qPCR etc. | cell line (PC3) | differential expression | expression | This essential role, coupled to the TRPM2-AS low-expression levels in healthy tissues, makes this ncRNA a suitable therapeutic target for further clinical studies. To get insights into the survival mechanism controlled by this molecule, we ablated its expression in prostate cancer cells and performed a genome-wide analysis of the transcripts differentially regulated in dying cells. | 26484139 | Lnc2Cancer |
| EL1366 | TRPM2-AS | prostate cancer | microarray, qPCR, knockdown etc. | prostate cancer tissue, cell lines (PNT1A, PC3 etc.) | up-regulated | N/A | TRPM2-AS is overexpressed in prostate cancer (PCa). The high expression of TRPM2-AS and its related gene signature were found to be linked to poor clinical outcome, with the related gene signature working also independently of the patient's Gleason score. Mechanistically, TRPM2-AS knockdown led to PCa cell apoptosis, with a transcriptional profile that indicated an unbearable increase in cellular stress in the dying cells, which was coupled to cell cycle arrest, an increase in intracellular hydrogen peroxide and activation of the sense TRPM2 gene. | 24931166 | Lnc2Cancer |
| EL1399 | TUG1 | prostate cancer | integrating analysis of sequence features and gene expression profiles | prostate cancer | up-regulated | N/A | sub-cellular localization-dependent function | 26975529 | |
| EL1416 | uc001lsz | prostate cancer | qPCR etc. | cell lines ((Du-145, PC-3) | up-regulated | N/A | We found that comparing with respective normal cell line, uc001lsz was lowly expressed in gastric cancer (AGS, MGC-803 and SGC-7901), lung cancer (A549) and liver cancer (SMMC-7721 and HepG2) cell lines, while only highly expressed in prostate cancer (Du-145 and PC-3) cell lines. | 24063685 | Lnc2Cancer |
| EL1431 | UCA1 | prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer |
| EL1431 | UCA1 | prostate cancer | qPCR, Western blot, knockdown etc. | prostate cancer tissue, cell lines (22RV1, PC3, LNCaP) | up-regulated | interaction | Herein, we found that UCA1 was abnormally upregulated in tumor tissues from PC patients, and patients with high UCA1 levels had a significantly poorer prognosis. Intriguingly, the mRNA and protein levels of KLF4 were significantly increased in tumor tissues, which was highly correlated to UCA1 levels. Moreover, UCA1 depletion inhibited the growth and induced apoptosis in PC3 and LNCaP cell lines. In addition, UCA1 loss-of-function could decrease KLF4 expression, subsequently, the downregulation of KRT6 and KRT13. Taken together, our study indicated that UCA1 had a crucial role in the tumorigenesis of PC. | 26550172 | Lnc2Cancer |
| EL1496 | XLOC_007697 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
| EL1497 | XLOC_008559 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |
| EL1499 | XLOC_009911 | prostate cancer | microarray, qPCR, knockdown etc. | urine, cell lines (PC3, LNCaP) | up-regulated | expression | We identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples and further characterized six long noncoding RNAs (AK024556, XLOC_007697, LOC100287482, XLOC_005327, XLOC_008559, and XLOC_009911) in prostatic adenocarcinoma tissue samples and compared them with matched normal tissues. Interestingly, these markers were also successfully detetced in patient urine samples and were found to be up-regulated when compared with normal urine. | 25513185 | Lnc2Cancer |